Vir Biotechnology, Inc. (NASDAQ:VIR – Get Rating) Director Saira Ramasastry sold 3,500 shares of the business’s stock in a transaction dated Thursday, June 1st. The shares were sold at an average price of $25.67, for a total value of $89,845.00. Following the sale, the director now directly owns 10,619 shares of the company’s stock, valued […]
Vir Biotechnology, Inc. (NASDAQ:VIR – Get Rating) insider Steven J. Rice sold 2,500 shares of Vir Biotechnology stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $25.67, for a total value of $64,175.00. Following the sale, the insider now directly owns 106,840 shares of the company’s stock, […]
Vir Biotechnology, Inc. (NASDAQ:VIR – Get Rating) gapped down before the market opened on Thursday . The stock had previously closed at $26.67, but opened at $25.67. Vir Biotechnology shares last traded at $25.89, with a volume of 100,878 shares trading hands. Analyst Ratings Changes VIR has been the topic of several research analyst reports. […]
Vir Biotechnology, Inc. (NASDAQ:VIR – Get Rating) major shareholder Endurance (Cayman) Ltd Svf sold 104,384 shares of the firm’s stock in a transaction on Wednesday, May 24th. The shares were sold at an average price of $26.15, for a total transaction of $2,729,641.60. Following the completion of the transaction, the insider now owns 17,178,585 shares […]
UBS Group AG raised its stake in shares of Vir Biotechnology, Inc. (NASDAQ:VIR – Get Rating) by 177.2% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 289,727 shares of the company’s stock after buying an additional 185,199 shares during the quarter. UBS Group […]